Cardiorenal benefits of finerenone: protecting kidney and heart

Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role...

Descripción completa

Detalles Bibliográficos
Autores: González Juanatey, José Ramón, Górriz, J.L., Ortiz, A., Valle, A., Soler, M.J., Facila, L.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21182
Acceso en línea:https://portalcientifico.sergas.gal//documentos/63f1b8d072e8fb4b23a7478a
http://hdl.handle.net/20.500.11940/21182
Access Level:acceso abierto
Palabra clave:Humans
Diabetes Mellitus, Type 2
Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid
Albuminuria
Diabetic Nephropathies
Renal Insufficiency, Chronic
Cardiovascular Diseases
Kidney
Fibrosis
Inflammation
Glucose
Sodium
AS Santiago
CHUS
id ES_250869f0660dcccffaebe7c77bee08ee
oai_identifier_str oai:runa.sergas.gal:20.500.11940/21182
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cardiorenal benefits of finerenone: protecting kidney and heartGonzález Juanatey, José RamónGórriz, J.L.Ortiz, A.Valle, A.Soler, M.J.Facila, L.HumansDiabetes Mellitus, Type 2Mineralocorticoid Receptor AntagonistsReceptors, MineralocorticoidAlbuminuriaDiabetic NephropathiesRenal Insufficiency, ChronicCardiovascular DiseasesKidneyFibrosisInflammationGlucoseSodiumAS SantiagoCHUSPersons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.Key messages: Despite inhibition of renin-angiotensin system and sodium-glucose cotransporter type 2, persons with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain on high cardiovascular (CV) residual risk. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis that is not targeted by traditional treatments. Finerenone is a nonsteroidal selective mineralocorticoid antagonist that decreases not only albuminuria, but also the risk of CKD progression, and CV risk in subjects with T2D and CKD.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/63f1b8d072e8fb4b23a7478ahttp://hdl.handle.net/20.500.11940/21182reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/211822026-06-12T08:40:47Z
dc.title.none.fl_str_mv Cardiorenal benefits of finerenone: protecting kidney and heart
title Cardiorenal benefits of finerenone: protecting kidney and heart
spellingShingle Cardiorenal benefits of finerenone: protecting kidney and heart
González Juanatey, José Ramón
Humans
Diabetes Mellitus, Type 2
Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid
Albuminuria
Diabetic Nephropathies
Renal Insufficiency, Chronic
Cardiovascular Diseases
Kidney
Fibrosis
Inflammation
Glucose
Sodium
AS Santiago
CHUS
title_short Cardiorenal benefits of finerenone: protecting kidney and heart
title_full Cardiorenal benefits of finerenone: protecting kidney and heart
title_fullStr Cardiorenal benefits of finerenone: protecting kidney and heart
title_full_unstemmed Cardiorenal benefits of finerenone: protecting kidney and heart
title_sort Cardiorenal benefits of finerenone: protecting kidney and heart
dc.creator.none.fl_str_mv González Juanatey, José Ramón
Górriz, J.L.
Ortiz, A.
Valle, A.
Soler, M.J.
Facila, L.
author González Juanatey, José Ramón
author_facet González Juanatey, José Ramón
Górriz, J.L.
Ortiz, A.
Valle, A.
Soler, M.J.
Facila, L.
author_role author
author2 Górriz, J.L.
Ortiz, A.
Valle, A.
Soler, M.J.
Facila, L.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Humans
Diabetes Mellitus, Type 2
Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid
Albuminuria
Diabetic Nephropathies
Renal Insufficiency, Chronic
Cardiovascular Diseases
Kidney
Fibrosis
Inflammation
Glucose
Sodium
AS Santiago
CHUS
topic Humans
Diabetes Mellitus, Type 2
Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid
Albuminuria
Diabetic Nephropathies
Renal Insufficiency, Chronic
Cardiovascular Diseases
Kidney
Fibrosis
Inflammation
Glucose
Sodium
AS Santiago
CHUS
description Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.Key messages: Despite inhibition of renin-angiotensin system and sodium-glucose cotransporter type 2, persons with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain on high cardiovascular (CV) residual risk. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis that is not targeted by traditional treatments. Finerenone is a nonsteroidal selective mineralocorticoid antagonist that decreases not only albuminuria, but also the risk of CKD progression, and CV risk in subjects with T2D and CKD.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/63f1b8d072e8fb4b23a7478a
http://hdl.handle.net/20.500.11940/21182
url https://portalcientifico.sergas.gal//documentos/63f1b8d072e8fb4b23a7478a
http://hdl.handle.net/20.500.11940/21182
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404733886693376
score 15,811543

Similares en LA Referencia